Multivariate analysis comparing survival among patients who underwent an allogeneic transplantation for the treatment of first chronic phase chronic myeloid leukemia from 1999 to 2004
| Variable . | n . | Relative risk of death (95% CI) . | P . |
|---|---|---|---|
| Main effect | |||
| No imatinib | 657 | 1.00* | |
| Imatinib | 181 | 0.63 (0.46-0.88) | .006† |
| Other significant covariates | |||
| Donor-recipient HLA match | < .001‡ | ||
| Matched sibling | 327 | 1.00* | |
| Well matched | 217 | 1.53 (1.10-2.13) | .011 |
| Partially matched | 160 | 1.90 (1.36-2.66) | < .001 |
| Mismatch | 92 | 2.57 (1.78-3.71) | < .001 |
| Unknown | 42 | 1.75 (1.02-3.00) | .042 |
| Graft type | |||
| BM | 570 | 1.00 | |
| PB | 268 | 1.51 (1.16-1.96) | .002† |
| Time from diagnosis to transplantation | |||
| ≤ 12 mo | 516 | 1.00 | |
| > 12 mo | 322 | 1.46 (1.15-1.85) | .002† |
| Variable . | n . | Relative risk of death (95% CI) . | P . |
|---|---|---|---|
| Main effect | |||
| No imatinib | 657 | 1.00* | |
| Imatinib | 181 | 0.63 (0.46-0.88) | .006† |
| Other significant covariates | |||
| Donor-recipient HLA match | < .001‡ | ||
| Matched sibling | 327 | 1.00* | |
| Well matched | 217 | 1.53 (1.10-2.13) | .011 |
| Partially matched | 160 | 1.90 (1.36-2.66) | < .001 |
| Mismatch | 92 | 2.57 (1.78-3.71) | < .001 |
| Unknown | 42 | 1.75 (1.02-3.00) | .042 |
| Graft type | |||
| BM | 570 | 1.00 | |
| PB | 268 | 1.51 (1.16-1.96) | .002† |
| Time from diagnosis to transplantation | |||
| ≤ 12 mo | 516 | 1.00 | |
| > 12 mo | 322 | 1.46 (1.15-1.85) | .002† |